CEL-SCI Corporation CVM

I still do not understand the delay.. NO TOXICITY has been established. Knowing that, even marginal effectiveness should get it approved as it is for treatment of a FATAL condition. I still think this is being slowi walked by the FDA to exhaust CVM funds so big pharma company can acquire at discount.

Wayne I bet she could seeit on your face!

Safety of multikine well established. There should be no need for any further trials

Don’t know where people are getting info regarding FDA approval. Effective orphan drug for terminal illness should not take another 2 years for approval. I remain concerned that big Pharma influencing FDA to slow walk multikine. Either they want to force a sale of CVM at bargain basement price or they simply do not want the competition. The FDA ignored data to approve COViD vaccine for CHILDREN. They are bought and paid for. This is not about helping people. It is about money and market share. I think it is VERY worrisome that a potentially $150 stock is under $5

These are not normal times. If the FDA can be bought off to poison children with a vaccine they don’t need - with a significant side effect profile - depriving cancer patients of a potentially life saving drug to appease big pharma competitors is chump change. Drug should have been approved by now.

Multikine is essentially an orphan drug. I am surprised it has taken this long for approval- esp given it’s proven effectiveness and lack of toxicity. Unfortunately we have seen with COVID vaccine data just how corrupt the FDA is. I would not be surprised if Big Pharma is enticing the FDA to slow walk approval so an established company can purchase CVM at a substantial discount. Judging by similar biotechs, with approval this may be a $200 stock.

You think AK has a picket line outside ASCO???

And yes it’s true when the Gov. Drops its data review it will kick AF so hard in the ass that it will fall off. He’s a very slimy man and has portrayed himself as more than he is.

Lymphokine has no real competitors for treatment of SCCA (squamous cell carcinoma) of H&N. It will get orphan status and fast approval when submitted. Do not understand delay. But delay seems to be stock in trade for this company as trials wasted maybe a decade due to poor administration and oversight.

Looking at the addressable market and comparing to similar companies, this is a &150-$200 stock with FDA approval. The CEO may be silent for legal reasons, but where are the takeover offers? Something is just not right. Phase III COMPLETED biotech should be much higher simply on speculation. Stock is being manipulated.